Quantification of nuclear transport inhibition by SARS-CoV-2 ORF6 using a broadly applicable live-cell dose-response pipeline

Tae Yeon Yoo*, Timothy Mitchison

Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA

* taeyeon_yoo@hms.harvard.edu

Abstract

SARS coronavirus ORF6 inhibits the classical nuclear import pathway to antagonize host antiviral responses. Several models were proposed to explain its inhibitory function, but quantitative measurement is needed for model evaluation and refinement. We report a broadly applicable live-cell method for calibrated dose-response characterization of the nuclear transport alteration by a protein of interest. Using this method, we found that SARS-CoV-2 ORF6 is ~5 times more potent than SARS-CoV-1 ORF6 in inhibiting bidirectional nuclear transport, due to differences in the NUP98-binding C-terminal region that is required for the inhibition. The N-terminal region was also required, but its membrane binding function was dispensable, since loss of the inhibitory function due to N-terminal truncation was rescued by forced oligomerization using a soluble construct. Based on these data, we propose that the hydrophobic N-terminal region drives oligomerization of ORF6 to multivalently cross-link the FG domains of NUP98 at the nuclear pore complex.

1 Introduction

2 Macromolecular transport across the nuclear envelope occurs through nuclear pore complexes (NPCs) and
 3 is tightly regulated in eukaryotic systems. The transport channel of the NPC is densely filled with
 4 intrinsically disordered regions of the FG-nucleoporins (FG-NUPs) enriched in phenylalanine-glycine
 5 repeats¹⁻³. The FG-repeat regions constitute a permeability barrier that specifically interacts with soluble
 6 transport carrier proteins, including importin-beta family proteins, to selectively facilitate their diffusion
 7 through the pore along with cargoes bound to them⁴⁻⁷. The classical nuclear import pathway involves
 8 importin beta-1 (KPNB1) as a transport carrier and a class of adaptor proteins called importin alphas
 9 (KPNAs) which bind classical nuclear localization signals (NLSs) in complex with KPNB1⁸. The classical
 10 nuclear export pathway is mediated by exportin-1 (CRM1/XPO1), another transport carrier in the
 11 importin-beta family, which directly binds to leucine-rich classical nuclear export signals⁹. Directionality
 12 of cargo transport is provided by compartment-specific assembly and disassembly of cargo-carrier
 13 complexes, which is mediated by the small GTPase RAN¹⁰⁻¹².

14
 15 Nucleocytoplasmic transport is required for several innate immune anti-viral pathways; for example, the
 16 interferon (IFN) response requires nuclear import of phosphorylated STAT1¹³. SARS coronaviruses, like
 17 several other viruses, were reported to inhibit the nucleocytoplasmic transport system of host cells during
 18 infection, resulting in reduced innate immune signaling¹⁴⁻¹⁹. A small protein that is unique to these viruses,
 19 Open Reading Frame 6 (ORF6), was shown to inhibit the KPNB1-mediated classical nuclear import
 20 pathway²⁰. Several inhibition mechanisms were proposed. Early studies on SARS-CoV-1 proposed that
 21 its ORF6 tethers KPNA2 to membranes of the endoplasmic reticulum (ER) and Golgi apparatus to
 22 sequester KPNB1²¹. Interaction of SARS-CoV-2 ORF6 with KPNA2 was also demonstrated^{16,18}. Recent
 23 studies on SARS-CoV-2 ORF6 identified NUP98-RAE1 complex, an NPC component possessing a long

FG-repeat domain, as a new binding partner of ORF6 and implicated this interaction in its inhibitory function^{18,22,23}. Miorin et al. proposed that ORF6 binding to the NUP98-RAE1 complex inhibits the docking of KPNB1 to the NPC¹⁸. Conversely, Kato et al. suggested that aberrant nucleocytoplasmic transport is caused by the ORF6 dislocating NUP98 from the NPCs to the cytoplasm²⁴.

Full understanding of how ORF6 inhibits nucleocytoplasmic transport requires quantitative measurement of the dose response function, i.e., the relationship between the intracellular expression level of ORF6 and the resulting reduction in the nuclear transport efficiency. Previous studies measured neither of the quantities but instead assessed the average effect of ORF6 overexpression on the steady-state localization of IFN-related transcription factors or artificial cargoes or on the downstream IFN signaling activities. Accurate dose-response characterization would also enable objective comparison of ORF6 activity between viral species and measurement of perturbation effects, for example the influence of variations in ORF6 sequence on its inhibitory function. Such comparison may contribute to understanding of different characteristics between SARS-CoV-1 and SARS-CoV-2 and the prediction of the innate immune response to new SARS-CoV-2 variants which may occur in the future.

One reason that inhibition of nuclear transport by ORF6 was not accurately quantified in previous studies was the lack of suitable assays. We previously developed optogenetic assays for quantification of nuclear import and export in living cells²⁵. Here, we apply them to measure inhibition by ORF6. We developed a simple measurement pipeline for calibrated quantification of the expression level of an untagged protein in single cells and applied it to measure ORF6 concentrations. In typical studies where results are averaged across many cells, variation in protein expression levels between cells is a technical problem. Conclusions based on bulk averages may not predict the behavior of individual cells whose expression level differs

from the mean value. By measuring ORF6 expression in individual cells, we took advantage of this unavoidable variation to populate the concentration axis of dose-response plots. We applied the resulting dose-response technology to characterize and compare the inhibitory functions of artificial and natural variants of the ORF6 protein, revealing the difference between SARS-CoV-1 and SARS-CoV-2 ORF6s and providing new mechanistic insights for their inhibitory actions. Our live cell dose-response pipeline could be adapted to any measurement where expression of an exogenous protein alters some function that can be quantified in individual cells.

Results

Pipeline for live-cell dose-response characterization of nuclear transport inhibition

We sought to develop a method for measuring the dose-dependent effect of expressing a protein of interest (POI) on the nuclear transport kinetics in individual live cells, with the constrain that the POI is untagged. ORF6 is a small (MW ~7 kDa), membrane-associated protein, so tagging it with a fluorescent protein might perturb its activity. To measure nuclear transport kinetics, we adopted the optogenetics-based assays that we recently developed to measure the rates of classical nuclear import and export in live cells²⁵. The assays use fluorescently labeled LOV2-based optogenetic probes that translocate from the cytoplasm to the nucleus or vice versa upon blue-light stimulation^{26,27}. The kinetics of the light-induced translocation is measured in each individual cell as proxy for the nuclear transport kinetics. The assays are performed using an automated microscopy platform with a low magnification (20x) objective lens and can readily process hundreds of cells in different conditions at different time points.

To express the POI and determine its level in individual cells while running the transport assay in parallel, we utilized a bicistronic expression system based on the 2A self-cleaving peptide²⁸ (Fig. 1a).

1 U2OS cells stably expressing the optogenetic nuclear import or export probe were transfected with a
 2 plasmid encoding GFP-2A-POI. Due to the self-cleaving activity of the 2A sequence, which occurs
 3 during translation²⁹, GFP and POI are produced at the same rate as separate polypeptides. This enables
 4 the estimation of the POI concentration based on the GFP fluorescence intensity without the use of
 5 direct tagging which might disrupt the function of the POI. The GFP intensity and the transport kinetics
 6 were repeatedly measured in hundreds of individual cells at 3–6-hour intervals after transfection. The
 7 GFP intensity was converted to absolute GFP concentration via a novel calibration procedure, described
 8 below. The resulting data shows a wide range of GFP concentration, typically ranging from 0 to 30 μM ,
 9 due to the stochasticity in the transient transfection as well as the time-dependent increase in the
 10 expression level. Plotting the nuclear transport rate (import or export) against the GFP concentration
 11 revealed the dose-response curve. To generate parameters from these curves, we fit them to a Hill
 12 function. As in pharmacokinetic-pharmacodynamic modeling³⁰, this fit should be considered descriptive
 13 rather than mechanistic, but it allowed quantitative comparisons across all the data.

14
 15 The GFP calibration is performed as follows (Fig. 1b, Supplementary Fig. 1): (Step 1) GFP expressing
 16 cells are imaged using the same microscope and image acquisition setting as in the dose-response
 17 characterization. The GFP intensity in each cell is quantified in the same way as in the dose-response
 18 characterization. (Step 2) Recombinant GFP is added to the culture at a certain concentration, and the
 19 same cells in the Step 1 are imaged again in the presence of GFP surrounding them. Cells would be
 20 brighter or darker than the background, depending on the relative concentration of the intracellular to the
 21 extracellular GFP concentration. (Step 3) Plotting the contrast between the intracellular and the
 22 background GFP intensity against the GFP intensity measured in Step 1 shows a linear relationship. A
 23 linear model is fitted to the relationship to determine the x-intercept, which corresponds to the GFP

intensity of a cell whose intracellular GFP concentration is the same as the concentration of the recombinant GFP added to the culture in Step 2. (Step 4) Steps 1 to 3 are repeated with different concentrations of added GFP to obtain the relationship between the GFP intensity and concentration. The slope of the linear model fitted to the relationship serves as the intensity-to-concentration conversion factor. Importantly, this method reports GFP concentration values independent of the optical parameters of the microscope such as the depth of field or illumination brightness (Supplementary Text).

We tested the dose-response pipeline with negative controls (Supplementary Fig. 2). When only GFP was expressed, the nuclear import rate was constant across the GFP concentration, indicating the absence of artifacts due to GFP overexpression. ORF10 and Candidate ORF15 are gene products of SARS-CoV-2 that have been reported to not affect the IFN signaling and therefore are not likely to alter the nuclear import^{16,31}. As expected, these proteins showed flat dose-response curves, confirming that co-expression of GFP and an inactive POI does not perturb transport.

Comparison of ORF6 activity between SARS coronaviruses

We applied the dose-response pipeline to compare the inhibitory effects of SARS-CoV-1 and SARS-CoV-2 ORF6s (denoted by ORF6^{CoV1} and ORF6^{CoV2}, respectively) on nuclear transport. The amino acid sequences of ORF6^{CoV1} and ORF6^{CoV2} are 69% identical; most of the variations lie in the C-terminal half, including the 2 amino acid C-terminal extension of ORF6^{CoV1} (Fig. 2a). We acquired dose-response curves of ORF6^{CoV1} and ORF6^{CoV2} on the nuclear import and export rates. The Hill function fit well to all the dose-response curves, providing parameters that reflect the amplitude of inhibition (A), half maximal inhibitory concentration (IC_{50}), and the steepness of the dose-response curve (n_H or Hill coefficient) (Fig. 2b). A and IC_{50} are measures of the efficacy and potency of ORF6 as a nuclear

transport inhibitor, respectively. In the nuclear import inhibition, ORF6^{CoV1} showed 4.7 times higher IC_{50} than ORF6^{CoV2} ($6.31 \pm 2.18 \mu\text{M}$ vs $1.35 \pm 0.07 \mu\text{M}$), indicating lower potency. The Hill coefficient was lower for ORF6^{CoV1} than ORF6^{CoV2} (1.50 ± 0.45 vs 4.36 ± 0.77), while the efficacy was similar ($0.43 \pm 0.09 \text{ min}^{-1}$ vs $0.47 \pm 0.01 \text{ min}^{-1}$). The higher potency of ORF6^{CoV2} in the nuclear import inhibition may underlie the previous observation that ORF6^{CoV2} suppressed IFN signaling more strongly than ORF6^{CoV1} when a cell population was transfected with the same amount of ORF6-expressing plasmid^{20,31}.

Both ORF6^{CoV1} and ORF6^{CoV2} inhibited the nuclear export, showing IC_{50} and Hill coefficient identical to those in the nuclear import inhibition (Fig. 2b). This result indicates that ORF6 does not act specifically on the KPNA1-mediated classical nuclear import pathway but broadly affects nuclear import and export pathways mediated by multiple transport carriers. This is not consistent with the previously proposed model in which the nuclear transport inhibition depends on the specific interaction between ORF6 and KPNA2^{16,21}, while supporting models proposing NPC impairments^{18,23}. The nuclear import and export rates at each dose of ORF6^{CoV1} and ORF6^{CoV2} showed a colinear relationship, suggesting that these two different ORF6s use the same inhibitory mechanism (Supplementary Fig. 3).

The absence of C-terminal Tyr-Pro extension largely explains the higher potency of SARS-CoV-2 ORF6

ORF6 is characterized by abundance of hydrophobic residues in the N-terminal region and negatively charged residues in the C-terminal region (Fig 3a). To identify regions in ORF6 that are accountable for the difference in the dose-response characteristics between ORF6^{CoV1} and ORF6^{CoV2}, we performed site-directed mutagenesis to substitute each cluster of mismatches in ORF6^{CoV2} with corresponding

1 ORF6^{CoV1} residues (Fig. 3a). None of the mutations affected the efficacy (A), while some of them
2 significantly altered the potency (IC_{50}) and Hill coefficient (n_H) of ORF6 (Fig. 3b, Supplementary Fig.
3 4). Notably, three mutations, E46K/N47K/K48N (#8), I60L (#12) and C-terminal addition of YP (#13),
4 attenuated both the potency and Hill coefficient of the ORF6^{CoV2} toward those of ORF6^{CoV1} (Fig. 3b,
5 Supplementary Fig. 4). Among them, the mutation #13 showed the strongest effect, increasing IC_{50} by a
6 factor of 2.5 and decreasing Hill coefficient by a factor of 1.7 (Fig. 3c). We verified the effect of this
7 mutation by removing YP at the C-terminus of ORF6^{CoV1} (#13r). The mutation #13r drastically
8 enhanced the potency of ORF6^{CoV1} by a factor of 7, making it even more potent than ORF6^{CoV2} (Fig. 3b,
9 c). This suggests that the lack of C-terminal YP mainly contributes to the higher potency of ORF6^{CoV2}.
10 Consistent with our results, a previous study observed that mutations #8 and #13 significantly decreased
11 the inhibitory effect of ORF6^{CoV2} on the IFN signaling activity²⁰.

12

13 **The N-terminal and C-terminal regions are simultaneously required for the inhibitory function of** 14 **SARS-CoV-2 ORF6**

15 To gain more insights into the inhibitory mechanism, we characterized additional artificial and natural
16 variants of ORF6^{CoV2}. The hydrophobic N-terminal region of ORF6 interacts with the membranes of ER
17 and Golgi apparatus; it has been previously shown that residues 2-37 of ORF6^{CoV1} are embedded in the
18 membrane³² and that the peptides of residues 4-24 and 22-42 of ORF6^{CoV2} bind the membrane³³. The
19 negatively charged C-terminal region is responsible for interactions with NUP98-RAE1 and
20 KPNA^{18,20,21,23}. Therefore, it is predicted that mutations in the C-terminal region of ORF6 would affect
21 its interactions with NUP98-RAE1 and/or KPNA while retaining the membrane binding. We found that
22 C-terminal truncation of 24 residues resulted in the complete loss of the inhibitory effect of ORF6^{CoV2}
23 on the nuclear import, and so did C-terminal 6-residue truncation, which had been discovered in

COVID-19 patients in Italy³⁴ (Fig. 4a). Together with the comparative mutational analysis of ORF6^{CoV1} and ORF6^{CoV2} (Fig. 3), these results suggest that the C-terminal end is crucial to the inhibitory function of ORF6. We also tested a point mutation, M58R, which has been shown to abolish the ability of ORF6^{CoV2} to bind NUP98-RAE1 while maintaining its KPNA binding¹⁸. This point mutation also resulted in the complete loss of the inhibitory function of ORF6^{CoV2}, suggesting that NUP98-RAE1 binding of the C-terminal region is essential while KPNA binding is not (Fig. 4a).

We also evaluated the influence of mutations in the N-terminal and middle regions on the inhibitory function of ORF6^{CoV2} (Fig. 4b). The peptide of C-terminal residues 43-61 has been previously shown to interact with NUP98-RAE1 complex¹⁸. We found that the peptide of residues 38-61 did not show a significant inhibitory effect on the nuclear import (Fig. 4b), indicating that NUP98-RAE1 binding alone is not sufficient for the transport inhibition. Alternative translation of ORF6^{CoV2} gene results in the lack of the first 18 residues³⁵, which we found to reduce the potency of ORF6^{CoV2} by a factor of 3.4 ($IC_{50} = 4.57 \pm 0.76 \mu\text{M}$) (Fig. 4b). A previous study discovered ORF6 having a 9-residue deletion from the central part (residues 22-30) in a SARS-CoV-2 strain passaged *in vitro* in the IFN-deficient Vero E6 cell³⁶. Although the authors predicted that the deletion would dramatically alter the structure of ORF6 binding to the membrane, the deletion did not affect the dose-response characteristics of the nuclear import inhibition (Fig. 4b). This is consistent with K23R/V24I/S25A and Y31V mutations (denoted by #2 and #3) not affecting the dose-response characteristics (Fig. 3 and Supplementary Fig. 4). Taken together, these mutational analyses suggest that the N-terminal and C-terminal regions are simultaneously required for the ORF6 activity in the nuclear transport inhibition, while the central region (22-30) is not important.

Membrane binding is not required for the inhibitory function of ORF6

We next sought to examine the localization of ORF6 using small epitope tags and immunofluorescence. Direct tagging of ORF6 with an epitope tag or fluorescent protein has been performed in previous studies to examine the subcellular localization or interactions with other proteins^{16,18,20-24}, but the effect of the tagging on the inhibitory function has not been evaluated. We characterized the dose responses of ORF6^{CoV2} N- or C-terminally tagged with three different epitope tags: ALFA³⁷, Flag, and HA. All three epitope tags attenuated the potency of ORF6^{CoV2} when positioned at the C-terminus (Fig. 5a, Supplementary Fig. 5). This is consistent with the observation that the ORF6^{CoV2} potency was sensitive to the C-terminal modifications (Fig. 3 and Fig. 4a). On the other hand, at the N-terminus of ORF6, ALFA and HA tags had negligible influence on the dose-response characteristics, while Flag tag rather increased the potency (Fig. 5a, Supplementary Fig. 5). These results suggest that the tagging location and the type of epitope tag should be carefully selected when studying small proteins and must be explicitly reported in publications.

We chose to use ALFA tag for subsequent immunofluorescence analyses since there is a well-characterized fluorophore-conjugated anti-ALFA single-domain antibody (“nanobody”) commercially available³⁷. U2OS cells were transfected with GFP-2A-ALFA-ORF6^{CoV2} or GFP-2A-ORF6^{CoV2}-ALFA for 24 hours. Prior to paraformaldehyde fixation, GFP concentration was measured to estimate the co-expressed ORF6 level as in the nuclear transport dose-response analysis (Fig 1b). The fixed cells were permeabilized with digitonin to preserve the intracellular membrane structure and then immunostained using the anti-ALFA nanobody and anti-NUP98 antibody. Interestingly, the N- and C-terminally tagged ORF6^{CoV2} showed distinct staining patterns (Fig. 5b). ALFA-ORF6^{CoV2} showed strong nuclear pore staining with negligible staining elsewhere throughout different expression levels. On the other hand,

ORF6^{CoV2}-ALFA was stained at the cytoplasmic membranes and the nuclear envelope so strongly that staining of individual nuclear pores was barely discernable. At high ORF6 concentrations, we found that NUP98 was dislocated from the NPC, consistent with a previous study²⁴ (Fig. 5b). However, the NUP98 dislocation was not noticeable at ORF6 concentrations that are low yet high enough to inhibit the nuclear transport, so it is unlikely to be directly involved in the nuclear transport inhibition.

The difference in the ALFA immunostaining patterns (Fig. 5b) could result from the membrane binding of the N-terminal region being disrupted by the proximal N-terminal ALFA tag but not by the distal C-terminal tag. If this is the case, the lack of effect of the N-terminal ALFA tag on the dose-response characteristics (Fig. 5a) would suggest that membrane binding is not required for the inhibitory function of ORF6^{CoV2}. However, the difference in the ALFA immunostaining patterns could also result from the membrane binding of the N-terminal region restricting the N-terminal ALFA tag from binding the anti-ALFA nanobody. To test this possibility, we examined the immunofluorescence localization of ORF6 having ALFA tags at both the N- and C-termini (ALFA-ORF6^{CoV2}-ALFA) (Fig. 5c). We found that this construct showed strong ALFA immunostaining at the nuclear pores, similar to ALFA-ORF6^{CoV2}. If the absence of the immunostained ALFA-ORF6^{CoV2} at the membranes was due to epitope inaccessibility rather than hindrance of membrane binding, ALFA-ORF6^{CoV2}-ALFA would have shown strong ALFA immunostaining at the membranes like ORF6^{CoV2}-ALFA did. Thus, the N-terminal ALFA tag inhibits the membrane binding of ORF6^{CoV2} but does not alter its inhibitory effect on the nuclear transport. This indicates that the role of the N-terminal region in the nuclear transport inhibition is not the membrane binding but something else.

Forced homo-oligomerization rescues the inhibitory function of N-terminally truncated ORF6

1 We next sought to investigate alternative roles of the N-terminal region of ORF6 in the transport
 2 inhibition. Several other proteins have also been reported to bind FG-NUPs and inhibit the carrier-
 3 mediated nuclear transport. Such proteins include wheat germ agglutinin³⁸ (WGA), hyperphosphorylated
 4 tau³⁹, C9orf72 dipeptide repeats⁴⁰, and vesicular stomatitis virus matrix (VSV M) protein^{41,42}. A
 5 common feature of these proteins is the ability to form protein aggregates or homo-oligomers which are
 6 presumably able to multivalently cross-link FG domains⁴³⁻⁴⁵. For example, WGA forms a dimer with
 7 eight binding sites for O-GlcNAc, a glycosylation abundant in the FG domains^{46,47}. A recent
 8 computational analysis predicted that ORF6 is also aggregate-prone due to the hydrophobic N-terminal
 9 region⁴⁸. Therefore, we hypothesized that the mechanistic role of the N-terminal region of ORF6 in the
 10 nuclear transport inhibition is to mediate aggregation or homo-oligomerization, while its membrane
 11 binding is rather coincidental.

12
 13 To test this hypothesis, we investigated whether the N-terminal region can be functionally replaced with
 14 an oligomerization domain derived from other proteins that do not bind membranes. We first used a
 15 chemically inducible oligomerization system based on the F36V mutant of FK506-binding protein 12
 16 (FKBP) and the B/B Homodimerizer ligand (equivalent to AP20187)⁴⁹ (Fig. 6a). Addition of the
 17 homodimerizer did not affect the dose-response characteristics of the full-length ORF6^{CoV2} or the N-
 18 terminal truncation of ORF6^{CoV2} (residues 38-61; CT), confirming the absence of unspecific effects of
 19 the homodimerizer on the dose response (Fig. 6a). When the CT was fused to FKBP, addition of the
 20 homodimerizer partially recovered the inhibitory function of the CT (Fig. 6a). The homodimerizer-
 21 dependent recovery further increased when the CT was fused to two FKBP in tandem, which
 22 presumably induce higher-order oligomerization (Fig. 6a). We also tested the tetramerization domain of
 23 p53 (residues 326-356; p53TD)^{50,51}, which is far smaller than the tandem FKBP (MW ~4 kDa vs ~24

kDa) and comparable to the truncated N-terminal region in size. We found that fusing p53TD also rescues the inhibitory function of the CT (Fig. 6b). We confirmed that the CT and the fusion proteins were localized at the nuclear pores without showing noticeable membrane localization (Fig. 6c, d, e). The recovery of the inhibitory function via forced homo-oligomerization suggests that the mechanistic role of the N-terminal region in the nuclear transport inhibition may be to drive oligomerization of ORF6 and that membrane binding is dispensable (Fig. 6f).

Having multiple NUP98-binding C-terminal regions, the ORF6 oligomer would have a high avidity for the multiple copies of NUP98 clustered at the NPC. The interaction with KPNA, on the other hand, would not be strengthened by homo-oligomerization because they diffuse freely as monomers. Consistent with this prediction, we found that forced homo-oligomerization increased the nuclear pore localization of the CT relative to the nucleoplasmic localization, which presumably results from the KPNA binding (Fig. 6c, d, e). Thus, we propose that ORF6 homo-oligomerizes to multivalently cross-link the FG domains of NUP98 at the NPC (Fig. 6f).

Discussion

We developed a broadly applicable pipeline for live-cell dose-response characterization of nuclear transport inhibitions. This combines the optogenetics-based measurement of nuclear transport kinetics²⁵ with measurement of protein expression level in individual cells. The protein level measurement does not rely on direct tagging and therefore is suitable for small proteins like SARS coronavirus ORF6. Both dose and response are calibrated in physical units, μM and min^{-1} , making the data reproducible between experiments and directly comparable across different conditions and microscopes. Here we chose to fit

1 the widely used Hill function to the dose-response data to obtain quantitative metrics, noting that more
2 mechanistic models may also be used to extract biophysical parameters in future studies.
3
4 The dose-response pipeline quantitatively revealed key mechanistic features of the inhibitory function of
5 ORF6. First, ORF6 inhibits multiple carrier-mediated bidirectional transport pathways. ORF6 showed
6 the same potency and Hill coefficient for inhibitions of KPNB1-mediated nuclear import and
7 CRM1/XPO1-mediated nuclear export (Fig. 2a). Moreover, a recent study showed that ORF6 disrupts
8 the nuclear export of mRNA²³, which is mediated by a variety of other export carriers⁵². Therefore, the
9 nuclear transport inhibition likely arises from a carrier unspecific perturbation of the nuclear transport
10 machinery, e.g., the NPC impairment, rather than from specific interactions with KPNAs. Second,
11 NUP98 binding of the C-terminal region is necessary but not sufficient for the inhibitory action of
12 ORF6. C-terminal modifications dramatically altered the dose-response characteristics of ORF6 (Fig. 3,
13 4 and 5). Most importantly, the NUP98 binding deficient mutation, M58R¹⁸, abolished the inhibitory
14 function of ORF6 (Fig 4a). Compared to ORF6^{CoV1}, ORF6^{CoV2} showed a higher potency in inhibiting the
15 nuclear transport in our study (Fig. 2), primarily due to differences in the C-terminal end. In another
16 study, ORF6^{CoV2} showed a stronger NUP98 binding than ORF6^{CoV1}²³. This correlation suggests that
17 NUP98 binding of the C-terminal region determines the potency of ORF6. The NUP98 binding C-
18 terminal region alone without the N-terminal region was not able to inhibit the nuclear transport,
19 indicating that the ORF6 function requires the joint action of N- and C-terminal regions (Fig. 5). Finally,
20 membrane binding of the N-terminal region is not required for the inhibitory function of ORF6.
21 Disrupting the membrane binding by N-terminally tagging the ORF6^{CoV2} with ALFA did not alter the
22 inhibitory dose-response characteristics (Fig. 5). The N-terminal region was able to be functionally
23 replaced with oligomerization domains that do not bind membranes (Fig. 6). Therefore, we argue that

the major role of the N-terminal region in the nuclear transport inhibition is to drive oligomerization, while the membrane binding is dispensable. Taken together, we propose that ORF6 forms oligomer via the N-terminal region to multivalently cross-link the FG domains of NUP98 via the C-terminal region (Fig. 6f). The long FG domain of NUP98 was found to interact *in vivo* with many other FG-NUPs of native human NPCs⁵³, so the cross-linking of the FG domains of NUP98 could have strong influence on the overall permeability of the FG barrier to cargo-carrier complexes.

Methods

Cell culture

U2OS cell lines (engineered from HTB-96, ATCC) were maintained in complete DMEM (low glucose (1g/L) Dulbecco's modified Eagle's medium (DMEM, Thermo Fisher, #10567022) supplemented with 10% Fetal Bovine Serum (FBS, Thermo Fisher, #A31605), 50 IU ml⁻¹ penicillin, and 50 µg ml⁻¹ streptomycin (Thermo Fisher, #15140122)) at 37°C in a humidified atmosphere with 5% CO₂. Cells were validated as mycoplasma free by PCR-based mycoplasma detection kit (ATCC, #30-1012K).

Plasmid cloning and reagent preparation

Plasmids encoding GFP-2A-ORF6 were generated by inserting EGFP-T2A sequence (copied from Addgene #140424 by PCR) at the 5' end of the ORF6 gene in pSecTag2 mammalian expression vector using Gibson Assembly. ORF6 mutants were generated by using Q5 Site-Directed Mutagenesis Kit (NEB, #E0554S) or QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, #200521). ALFA (PSRLEEELRRRLTEP), HA and Flag tags were attached to the N- and/or C-terminal end of ORF6 with Gly-Ser linker. Oligonucleotides for PCRs were purchased from IDT or Genewiz. All the plasmids generated in this study were verified by Sanger sequencing (Genewiz). The recombinant His6-EGFP

used in the GFP intensity calibration (Fig. 1b) was expressed in Rosetta 2 (DE3) competent cells (Millipore Sigma #71400) using pDual-EGFP plasmid (Addgene, #63215), purified using HisPur™ Ni-NTA Spin Columns (Thermo Fisher, #88226) via a standard protocol, and dialyzed in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 2 mM DTT. The concentration was determined based on the 488 nm absorbance and the previously reported value⁵⁴ of the extinction coefficient of EGFP at 488 nm, which is 53,300 M⁻¹cm⁻¹. The purified His6-EGFP was aliquoted, snap-frozen in liquid nitrogen, and stored in -80°C.

Dose-response characterization of nuclear transport inhibition

Live-cell imaging

U2OS stable cell lines stably expressing H2A-Halo and NES-mCherry-LINuS (import probe) or NLS-mCherry-LEXY (export probe) were generated in our previous study²⁵ and were used in this study for measuring the dose-dependent effect of ORF6 on the nuclear transport kinetics. Cells were seeded at ~10,000 cells per well in an eight-well chambered coverslip (ibidi, #80826) with 250 µl complete DMEM. On the next day, cells in each well were transfected with a plasmid encoding GFP-2A-POI (protein of interest) using TransIT-2020 transfection reagent (Mirus #5404) as follows: 260 ng plasmid was complexed with 0.78 µl reagent in 26 µl Opti-MEM™ I Reduced Serum Medium (Thermo Fisher, #31985062) for 20 minutes. The complex was diluted in 263 µl prewarmed imaging media (low glucose (1g/L) DMEM without phenol red (Thermo Fisher, #11054020) supplemented with 10% FBS, 50 IU ml⁻¹ penicillin, 50 µg ml⁻¹ streptomycin, and GlutaMAX Supplement (Thermo Fisher, #35050061)) containing 500 nM JF646-HaloTag ligand (gift from Luke Lavis) and added to the well. For the FKBP-based forced oligomerization experiments (Fig. 6a), 500 nM B/B Homodimerizer (Takara, #635058) was also added. After 2.5–6 hours of the transfection, cells were continually imaged for the

simultaneous measurement of the nuclear transport kinetics and GFP intensity for ~24 hours. Cage microscope incubator (OkoLab) was used to maintain the cells at 37°C in 5% CO₂ with high humidity during imaging.

Live-cell imaging for the simultaneous measurement of the nuclear transport kinetics and GFP intensity was performed on a Nikon Ti motorized inverted microscope with Perfect Focus System, using spinning disk confocal scanner (CSU-X1, Yokagawa) with Spectral Applied Research Aurora Borealis modification, motorized stage and shutters (Proscan II, Prior), scientific complementary metal-oxide-semiconductor (sCMOS) camera (Flash4.0 V3, Hamamatsu), laser merge module (LMM-5, Spectral Applied Research), CFI Plan Apo 20x/0.75NA objective lens (Nikon), and ZT445/514/561/640tpc (Chroma) polychroic mirror. mCherry-labeled import/export probes were imaged using 561-nm laser and ET605/70m emission filter (Chroma), while H2A-Halo:JF646 was imaged using 642-nm laser and ET700/75m emission filter (Chroma). Live-cell time-lapse images were acquired through a ~11-min imaging cycle that consisted of two acquisition phases: pre-activation and activation. Throughout the cycle, the mCherry-labeled transport probes and H2A-Halo:JF646 were imaged every 10 s with 100-ms exposure time. Three frames (30 s) were acquired in the pre-activation phase to determine the baseline nuclear localization of the probe, followed by a 10-min activation phase (61 frames) in which the optogenetic transport probes were activated by 200-ms exposure to the activation laser (447 nm) every 10 s. The activation laser also excites GFP, of which images were collected using ET480/40m emission filter (Chroma). To increase the throughput, the imaging cycle was executed at three different fields simultaneously. The imaging cycle was repeated at 3–6-hour interval at different wells, which was fully automated by using Journal macro in MetaMorph Software. The power of the 447-nm activation laser was optimized based on the nuclear export rate vs. laser power curve, to the lowest saturation level

where a small variation of the power does not influence the transport rate. No sign of photobleaching or photodamaging was noticed when the imaging cycle was repeated every hour for 24 hours at the same field.

Computational image analysis

Custom Python codes were used for quantitative image analysis of the time-lapse images. The quantification of the nuclear transport kinetics was performed as described previously²⁵. Briefly, cell nuclei were segmented based on H2A-Halo:JF646 images using U-Net convolutional neural network trained on manually annotated U2OS nuclei images⁵⁵ and tracked using Trackpy package (v0.4.1, 10.5281/zenodo.1226458). Then, for each nucleus, the time-trajectory of the mean nuclear mCherry intensity was measured and normalized such that the average intensity during pre-activation phase was 1 and the background intensity was 0. The following monoexponential decay model was fitted to the normalized nuclear mCherry intensity trajectory in the activation phase to determine the nuclear transport rate k :

$$y = (1 - b) \exp(-kt) + b$$

When the import probe is used, k corresponds to the import rate and b is > 1 (i.e. y increases over time), while when the export probe is used, k corresponds to the export rate and b is < 1 (i.e. y decreases over time). Trust region reflective least-squares algorithm was used for the nonlinear regression. The fitting result was excluded from further analyses if it met one or more of the following criteria: (1) the fitting algorithm did not converge; (2) there were too many missing time points in the nuclear intensity trajectory (i.e. incomplete nucleus tracking); (3) reduced chi-squared statistics was too large; (4) $|1-b|$ was too small; and (5) k was abnormally large.

The GFP images were corrected for camera dark noise and uneven illumination. Then, for each nucleus, mean GFP intensity was measured and converted to a concentration using the conversion factor obtained from the intensity calibration procedure described in Fig 1b and below. Dose-response curve was generated by plotting the nuclear transport rate (k) against the GFP concentration (C). The raw data points were logarithmically binned by the GFP concentration within the range between 0.1 μ M and 40 μ M. Median and interquartile range (IQR) were calculated in each bin and plotted as an error bar in the dose-response curve. Using the Levenberg-Marquardt least squares algorithm, the following Hill function was fitted to the binned median values:

$$k = \frac{A}{1 + \left(\frac{C}{IC_{50}}\right)^{n_H}} + y_{\text{inf}}$$

A is the amplitude of the inhibition (i.e., efficacy), IC_{50} the half-maximal inhibitory concentration (i.e., potency), and n_H the Hill coefficient.

GFP intensity calibration

The GFP intensity calibration (Fig. 1b) was performed every 2-3 weeks or whenever there was a major change in the microscope (e.g., laser realignment). For the calibration, the U2OS stable cell line expressing H2A-Halo was transfected with the GFP-2A-ORF6 plasmid and prepared in an 8-well chamber slide in the same way as in the dose-response characterization. GFP and H2A-Halo:JF646 were imaged using the same microscope setting as in the dose-response characterization at ~ 10 different stage positions within a well. While the sample was on the stage, the recombinant GFP was added to the well at a certain concentration, and GFP and H2A-Halo:JF646 were imaged again at the same stage positions. This procedure was repeated at different wells with ~ 5 different concentrations of the added recombinant GFP, ranging from 0 to 5 μ M. The GFP fluorescence intensities of each cell before and

after adding the recombinant GFP (I and I_{in} , respectively) were quantified in the same way as in the dose-response characterization. The extracellular background GFP intensity (I_{ex}) in the presence the added recombinant GFP was determined by blurring the image with a gaussian filter with sigma = 2 pixels and finding the most frequent intensity value. For each recombinant GFP concentration (C), $I_{in} - I_{ex}$ was plotted against I . A linear model was fitted to determine the x-intercept (I_0). The slope of the linear model fitted to the plot of I_0 against C was used as the intensity-to-concentration conversion factor. Levenberg-Marquardt least squares algorithm was used for the linear regressions.

Immunofluorescence

Sample preparation

U2OS cells were seeded at ~10,000 cells per well in a glass-bottom eight-well chambered coverslip (ibidi, #80827) with 250 μ l complete DMEM. On the next day, cells in each well were transfected with a plasmid encoding GFP-2A-POI using TransIT-2020 transfection reagent as described above, where POI is an epitope tagged protein (e.g., ALFA-ORF6^{CoV2} and ORF6-ALFA^{CoV2}). After ~24 hours of transfection, GFP images were acquired to determine the concentration of POI as described above. Then, cells were fixed using 2% PFA/PBS for 20 min at RT, permeabilized using 25 μ g/ml digitonin (Millipore Sigma, #300410) in PBS for 20 min at RT, and blocked using 1% BSA/PBS for 1 hour at RT. AF647-conjugated anti-ALFA single-domain antibody (NanoTag, #N1502-AF647) and anti-NUP98 rabbit monoclonal antibody (C39A3, Cell Signaling, #2598) were diluted by factors of 500 and 50 in 1% BSA/PBS, respectively. Cells were incubated with the diluted antibodies overnight at 4°C in a humidified chamber. Then, cells were incubated with goat anti-rabbit secondary antibody conjugated with AF568 (Thermo Fisher Scientific, #A11036) diluted (1:1,000 ratio) in 1% BSA/PBS for 1 hour at RT. Cells were washed in PBS for 5 min three times after each incubation step.

Image acquisition & visualization

Immunofluorescence images were acquired using a Nikon Ti motorized inverted microscope equipped with Perfect Focus System, Yokagawa CSU-X1 spinning disk confocal, Nikon LUN-F XL solid state laser combiner, Hamamatsu ORCA-Fusion BT CMOS camera (6.5 μm^2 photodiode), and Prior Proscan III motorized stage and shutters. CFI Plan Apo Lambda 100 $\times$ /1.45-NA oil objective lens (Nikon) and Di01-T405/488/568/647 polychroic mirror (Semrock) and 200 ms exposure time were commonly used for all channels. 488-nm laser and ET525/50m filter (Chroma) were used for GFP imaging; 561-nm laser and ET605/52m filter (Chroma) for AF568; and 640-nm laser and ET705/72m filter (Chroma) for AF647. NIS-Elements software was used to control the hardware. OMERO.figure was used for image visualization. The same lookup table (LUT) was used for the same channel and the same construct, while the minimum was commonly set to the dark current noise of the camera (=100).

Statistical information

All reported uncertainties of the parameter estimates are the standard errors. Data distribution was assumed to be normal in the uncertainty estimations, but this was not formally tested. Each dose-response curve consists of data acquired on at least 2 different days, and the total number of cells per dose-response curve is reported in figure legend. Batch effect was closely examined, but not detected.

Acknowledgments

We thank Prof. Pamela Silver (Harvard Medical School, Boston, MA) and the members of the Silver laboratory, especially Rui Tong Quek and Dr. Tai Ng, for providing plasmids, reagents, and comments; Dr. James Pelletier (Centro Nacional de Biotecnología, Madrid, Spain) for sharing the idea on GFP

intensity calibration; and Dr. Luke Lavis (Janelia Research Campus, Ashburn, VA) for providing JF646 dye. We also thank the Nikon Imaging Center (Harvard Medical School) for help with light microscopy.

This study was supported by NIH grant R35GM131753, a sponsored research award from AbbVie Inc. and postdoctoral fellowship (T.Y.Y) F32GM131585.

Author contributions: T.Y.Y. and T.J.M. conceived the study and wrote the manuscript. T.Y.Y. designed and performed the experiments and analyzed the data with input from T.J.M.

Competing interests: The authors declare no competing interests.

References

- 1 Lin, D. H. & Hoelz, A. The Structure of the Nuclear Pore Complex (An Update). *Annu Rev Biochem* **88**, 725-783, doi:10.1146/annurev-biochem-062917-011901 (2019).
- 2 Kim, S. J. *et al.* Integrative structure and functional anatomy of a nuclear pore complex. *Nature* **555**, 475-482, doi:10.1038/nature26003 (2018).
- 3 Denning, D. P., Patel, S. S., Uversky, V., Fink, A. L. & Rexach, M. Disorder in the nuclear pore complex: the FG repeat regions of nucleoporins are natively unfolded. *Proc Natl Acad Sci U S A* **100**, 2450-2455, doi:10.1073/pnas.0437902100 (2003).
- 4 Feldherr, C. M. & Akin, D. The location of the transport gate in the nuclear pore complex. *J Cell Sci* **110 (Pt 24)**, 3065-3070 (1997).
- 5 Keminer, O. & Peters, R. Permeability of single nuclear pores. *Biophys J* **77**, 217-228, doi:10.1016/S0006-3495(99)76883-9 (1999).

- 1 6 Ribbeck, K. & Gorlich, D. Kinetic analysis of translocation through nuclear pore complexes.
2 *EMBO J* **20**, 1320-1330, doi:10.1093/emboj/20.6.1320 (2001).
- 3 7 Fried, H. & Kutay, U. Nucleocytoplasmic transport: taking an inventory. *Cell Mol Life Sci* **60**,
4 1659-1688, doi:10.1007/s00018-003-3070-3 (2003).
- 5 8 Lange, A. *et al.* Classical nuclear localization signals: definition, function, and interaction with
6 importin alpha. *J Biol Chem* **282**, 5101-5105, doi:10.1074/jbc.R600026200 (2007).
- 7 9 Stade, K., Ford, C. S., Guthrie, C. & Weis, K. Exportin 1 (Crm1p) is an essential nuclear export
8 factor. *Cell* **90**, 1041-1050, doi:10.1016/s0092-8674(00)80370-0 (1997).
- 9 10 Christie, M. *et al.* Structural Biology and Regulation of Protein Import into the Nucleus. *J Mol*
10 *Biol* **428**, 2060-2090, doi:10.1016/j.jmb.2015.10.023 (2016).
- 11 11 Matsuura, Y. Mechanistic Insights from Structural Analyses of Ran-GTPase-Driven Nuclear
12 Export of Proteins and RNAs. *J Mol Biol* **428**, 2025-2039, doi:10.1016/j.jmb.2015.09.025
13 (2016).
- 14 12 Macara, I. G. Transport into and out of the nucleus. *Microbiol Mol Biol Rev* **65**, 570-594, table of
15 contents, doi:10.1128/MMBR.65.4.570-594.2001 (2001).
- 16 13 Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. *Nat Rev Immunol* **14**,
17 36-49, doi:10.1038/nri3581 (2014).
- 18 14 Tessier, T. M., Dodge, M. J., Prusinkiewicz, M. A. & Mymryk, J. S. Viral Appropriation: Laying
19 Claim to Host Nuclear Transport Machinery. *Cells* **8**, doi:10.3390/cells8060559 (2019).
- 20 15 Lei, X. *et al.* Activation and evasion of type I interferon responses by SARS-CoV-2. *Nat*
21 *Commun* **11**, 3810, doi:10.1038/s41467-020-17665-9 (2020).
- 22 16 Xia, H. *et al.* Evasion of Type I Interferon by SARS-CoV-2. *Cell Rep* **33**, 108234,
23 doi:10.1016/j.celrep.2020.108234 (2020).

1 17 Sajidah, E. S., Lim, K. & Wong, R. W. How SARS-CoV-2 and Other Viruses Build an Invasion
2 Route to Hijack the Host Nucleocytoplasmic Trafficking System. *Cells* **10**,
3 doi:10.3390/cells10061424 (2021).

4 18 Miorin, L. *et al.* SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and
5 antagonize interferon signaling. *Proc Natl Acad Sci U S A* **117**, 28344-28354,
6 doi:10.1073/pnas.2016650117 (2020).

7 19 Yarbrough, M. L., Mata, M. A., Sakthivel, R. & Fontoura, B. M. Viral subversion of
8 nucleocytoplasmic trafficking. *Traffic* **15**, 127-140, doi:10.1111/tra.12137 (2014).

9 20 Kimura, I. *et al.* Sarbecovirus ORF6 proteins hamper induction of interferon signaling. *Cell Rep*
10 **34**, 108916, doi:10.1016/j.celrep.2021.108916 (2021).

11 21 Frieman, M. *et al.* Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1
12 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi
13 membrane. *J Virol* **81**, 9812-9824, doi:10.1128/JVI.01012-07 (2007).

14 22 Gordon, D. E. *et al.* A SARS-CoV-2 protein interaction map reveals targets for drug
15 repurposing. *Nature* **583**, 459-468, doi:10.1038/s41586-020-2286-9 (2020).

16 23 Addetia, A. *et al.* SARS-CoV-2 ORF6 Disrupts Bidirectional Nucleocytoplasmic Transport
17 through Interactions with Rae1 and Nup98. *mBio* **12**, doi:10.1128/mBio.00065-21 (2021).

18 24 Kato, K. *et al.* Overexpression of SARS-CoV-2 protein ORF6 dislocates RAE1 and NUP98 from
19 the nuclear pore complex. *Biochem Biophys Res Commun* **536**, 59-66,
20 doi:10.1016/j.bbrc.2020.11.115 (2021).

21 25 Yoo, T. Y. & Mitchison, T. J. O-GlcNAc modification of nuclear pore complexes accelerates
22 bidirectional transport. *J Cell Biol* **220**, doi:10.1083/jcb.202010141 (2021).

1 26 Niopek, D. *et al.* Engineering light-inducible nuclear localization signals for precise
2 spatiotemporal control of protein dynamics in living cells. *Nat Commun* **5**, 4404,
3 doi:10.1038/ncomms5404 (2014).

4 27 Niopek, D., Wehler, P., Roensch, J., Eils, R. & Di Ventura, B. Optogenetic control of nuclear
5 protein export. *Nat Commun* **7**, 10624, doi:10.1038/ncomms10624 (2016).

6 28 Szymczak, A. L. & Vignali, D. A. Development of 2A peptide-based strategies in the design of
7 multicistronic vectors. *Expert Opin Biol Ther* **5**, 627-638, doi:10.1517/14712598.5.5.627 (2005).

8 29 de Felipe, P. *et al.* E unum pluribus: multiple proteins from a self-processing polyprotein. *Trends*
9 *Biotechnol* **24**, 68-75, doi:10.1016/j.tibtech.2005.12.006 (2006).

10 30 Goutelle, S. *et al.* The Hill equation: a review of its capabilities in pharmacological modelling.
11 *Fundam Clin Pharmacol* **22**, 633-648, doi:10.1111/j.1472-8206.2008.00633.x (2008).

12 31 Olson, E. *et al.* High-content screening of coronavirus genes for innate immune suppression
13 reveals enhanced potency of SARS-CoV-2 proteins. (2021).

14 32 Zhou, H. *et al.* The N-terminal region of severe acute respiratory syndrome coronavirus protein 6
15 induces membrane rearrangement and enhances virus replication. *J Virol* **84**, 3542-3551,
16 doi:10.1128/JVI.02570-09 (2010).

17 33 O'Keefe, S. *et al.* Ipomoeassin-F inhibits the in vitro biogenesis of the SARS-CoV-2 spike
18 protein and its host cell membrane receptor. *J Cell Sci* **134**, doi:10.1242/jcs.257758 (2021).

19 34 Delbue, S. *et al.* Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a
20 stop codon in the ORF 6 protein. *Emerg Microbes Infect* **10**, 252-255,
21 doi:10.1080/22221751.2021.1884003 (2021).

22 35 Finkel, Y. *et al.* The coding capacity of SARS-CoV-2. *Nature* **589**, 125-130,
23 doi:10.1038/s41586-020-2739-1 (2021).

1 36 Riojas, M. A. *et al.* A Rare Deletion in SARS-CoV-2 ORF6 Dramatically Alters the Predicted
2 Three-Dimensional Structure of the Resultant Protein. *bioRxiv*, doi:10.1101/2020.06.09.134460
3 (2020).

4 37 Gotzke, H. *et al.* The ALFA-tag is a highly versatile tool for nanobody-based bioscience
5 applications. *Nat Commun* **10**, 4403, doi:10.1038/s41467-019-12301-7 (2019).

6 38 Finlay, D. R., Newmeyer, D. D., Price, T. M. & Forbes, D. J. Inhibition of in vitro nuclear
7 transport by a lectin that binds to nuclear pores. *J Cell Biol* **104**, 189-200,
8 doi:10.1083/jcb.104.2.189 (1987).

9 39 Eftekharzadeh, B. *et al.* Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's
10 Disease. *Neuron* **99**, 925-940 e927, doi:10.1016/j.neuron.2018.07.039 (2018).

11 40 Shi, K. Y. *et al.* Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block
12 nuclear import and export. *Proc Natl Acad Sci U S A* **114**, E1111-E1117,
13 doi:10.1073/pnas.1620293114 (2017).

14 41 Petersen, J. M., Her, L. S., Varvel, V., Lund, E. & Dahlberg, J. E. The matrix protein of vesicular
15 stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with
16 nuclear pore complexes. *Mol Cell Biol* **20**, 8590-8601, doi:10.1128/MCB.20.22.8590-8601.2000
17 (2000).

18 42 Faria, P. A. *et al.* VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. *Mol Cell* **17**,
19 93-102, doi:10.1016/j.molcel.2004.11.023 (2005).

20 43 Gaudin, Y., Barge, A., Ebel, C. & Ruigrok, R. W. Aggregation of VSV M protein is reversible
21 and mediated by nucleation sites: implications for viral assembly. *Virology* **206**, 28-37,
22 doi:10.1016/s0042-6822(95)80016-6 (1995).

- 1 44 Gotz, J., Halliday, G. & Nisbet, R. M. Molecular Pathogenesis of the Tauopathies. *Annu Rev*
2 *Pathol* **14**, 239-261, doi:10.1146/annurev-pathmechdis-012418-012936 (2019).
- 3 45 Mori, K. *et al.* The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat
4 proteins in FTL/ALS. *Science* **339**, 1335-1338, doi:10.1126/science.1232927 (2013).
- 5 46 Schwefel, D. *et al.* Structural basis of multivalent binding to wheat germ agglutinin. *J Am Chem*
6 *Soc* **132**, 8704-8719, doi:10.1021/ja101646k (2010).
- 7 47 Li, B. & Kohler, J. J. Glycosylation of the nuclear pore. *Traffic* **15**, 347-361,
8 doi:10.1111/tra.12150 (2014).
- 9 48 Flores-Leon, M., Lazaro, D. F., Shvachiy, L., Krisko, A. & Outeiro, T. F. In silico analysis of the
10 aggregation propensity of the SARS-CoV-2 proteome: Insight into possible cellular pathologies.
11 *Biochim Biophys Acta Proteins Proteom* **1869**, 140693, doi:10.1016/j.bbapap.2021.140693
12 (2021).
- 13 49 Clackson, T. *et al.* Redesigning an FKBP-ligand interface to generate chemical dimerizers with
14 novel specificity. *Proc Natl Acad Sci U S A* **95**, 10437-10442, doi:10.1073/pnas.95.18.10437
15 (1998).
- 16 50 Jeffrey, P. D., Gorina, S. & Pavletich, N. P. Crystal structure of the tetramerization domain of the
17 p53 tumor suppressor at 1.7 angstroms. *Science* **267**, 1498-1502, doi:10.1126/science.7878469
18 (1995).
- 19 51 Clore, G. M. *et al.* High-resolution structure of the oligomerization domain of p53 by
20 multidimensional NMR. *Science* **265**, 386-391, doi:10.1126/science.8023159 (1994).
- 21 52 Carmody, S. R. & Wente, S. R. mRNA nuclear export at a glance. *J Cell Sci* **122**, 1933-1937,
22 doi:10.1242/jcs.041236 (2009).

- 1 53 Ma, J., Goryaynov, A. & Yang, W. Super-resolution 3D tomography of interactions and
2 competition in the nuclear pore complex. *Nat Struct Mol Biol* **23**, 239-247,
3 doi:10.1038/nsmb.3174 (2016).
- 4 54 Shimizu, A., Shiratori, I., Horii, K. & Waga, I. Molecular evolution of versatile derivatives from
5 a GFP-like protein in the marine copepod *Chiridius poppei*. *PLoS One* **12**, e0181186,
6 doi:10.1371/journal.pone.0181186 (2017).
- 7 55 Caicedo, J. C. *et al.* Evaluation of Deep Learning Strategies for Nucleus Segmentation in
8 Fluorescence Images. *Cytometry A* **95**, 952-965, doi:10.1002/cyto.a.23863 (2019).

Fig. 1. Calibrated dose-response characterization of nuclear transport alteration by exogenous protein expression. **a**, U2OS cell line stably expressing H2A-Halo and optogenetic nuclear import (NES-mCherry-LINuS) or export probe (NLS-mCherry-NEXY) was transfected with a plasmid encoding GFP-2A-POI (protein of interest). Due to the 2A self-cleavage sequence, GFP and POI are produced at the same rate as separate polypeptides. The rate of the light-induced nuclear/cytoplasmic translocation of the transport probe and GFP intensity were simultaneously measured in individual cells. The measurement was repeated at 3–6-hr interval for ~24 hrs after the transfection. The GFP intensity was converted to GFP concentration via calibration. The Hill function was fitted to the relationship between the nuclear transport rate and GFP concentration (“dose-response curve”) to obtain the dose-response parameters. Scale bar 50 μm . **b**, GFP intensity calibration procedure. (Step 1) Measure GFP intensity (I) of individual cells in the same way as in the dose-response characterization. (Step 2) Add a known concentration ($C \mu\text{M}$) of recombinant GFP to the culture and measure the intracellular and extracellular GFP intensities (I_{in} and I_{ex}). (Step 3) Fit a linear model to the plot of $I_{in} - I_{ex}$ vs I to determine the x-intercept (I_0), which is the GFP intensity equivalent to the concentration C . (Step 4) Repeat Steps 1 to 3 with different C ’s and fit a linear model to the plot of I_0 vs C to determine the slope, which serves as the intensity-to-concentration conversion factor. Example data is shown in Supplementary Fig. 1.

Fig. 2. SARS-CoV-2 ORF6 is more potent than SARS-CoV-1 ORF6 in inhibiting bidirectional nuclear transport. **a**, Amino acid sequences of SARS-CoV-1 and SARS-CoV-2 ORF6s. Dots indicate the mismatches. **b**, Dose-response curves for (top) the nuclear import and (bottom) export inhibition by (left) SARS-CoV-1 and (right) SARS-CoV-2 ORF6s. $n > 2900$ cells for each combination. Green circles are the raw data points. Black error bar represents median and interquartile range in each bin. Black line and shaded area represent the best Hill function fit and corresponding 95% confidence interval, respectively. The parameter estimates and standard errors are shown in the plots.

Fig. 3. The lack of C-terminal Tyr-Pro mainly contributes to the higher potency of SARS-CoV-2 ORF6. **a**, Notation of SARS-CoV-1 and SARS-CoV-2 ORF6 variants. **b**, Plot of IC_{50} vs n_H for each ORF6 variant. Error bar represents the standard error of the parameter estimate. $n > 1000$ cells for each variant. **c**, Dose-response curves for the nuclear import inhibition by (left) #13r (deletion of YP from the C-terminal end of ORF6^{CoV1}) and (right) #13 (addition of YP to the C-terminus of ORF6^{CoV2}). Green circles are the raw data points. Black error bar represents median and interquartile range in each bin. Black line and shaded area represent the best Hill function fit and the corresponding 95% confidence interval, respectively. The parameter estimates and standard errors are shown in the plots. Dotted line is the best Hill function fit for the (left) ORF6^{CoV1} and (right) ORF6^{CoV2} wild types shown for comparison. The dose-response curves for the other variants are shown in Supplementary Figure 4.

Fig. 4. The N-terminal and C-terminal regions are simultaneously required for ORF6 activity.

Dose-response curves for the nuclear import inhibition by **a**, ORF6^{CoV2} WT (black circles), residues 1-37 (yellow upward-pointing triangles), residues 1-55 (green squares), and M58R mutant (red downward-pointing triangles); and **b**, WT (black circles), residues 38-61 (yellow upward-pointing triangles), residues 19-61 (green squares), and Δ22-30 mutant (red downward-pointing triangles). $n > 1100$ cells for each variant. Error bars show the median and interquartile range in each bin. Shaded area represents 95% confidence interval of the best Hill function fit. Fits are not shown for the dose-response curves that failed to reject the null hypothesis that the inhibition amplitude (A) is zero ($\alpha = 0.05$).

Fig. 5. Membrane binding is not required for the inhibitory function of ORF6. U2OS cells were transfected with GFP-2A-ALFA-ORF6^{CoV2} or GFP-2A-ORF6^{CoV2}-ALFA so that ORF6^{CoV2} N- or C-terminally tagged with ALFA was co-expressed with GFP. **a**, The dose response curves for the nuclear import inhibition by (left) ALFA-ORF6^{CoV2} and (right) ORF6^{CoV2}-ALFA. $n > 1000$ cells for each. **b**, Representative NUP98 and ALFA immunofluorescence images of (left) ALFA-ORF6^{CoV2} and (right)

1 ORF6^{CoV2}-ALFA at low and high GFP concentrations when focused on the basal plane (“bottom”) and
2 midplane (“mid”) of the nucleus. **c**, Representative NUP98 and ALFA immunofluorescence image of
3 ALFA-ORF6^{CoV2}-ALFA when focused on the midplane of the nucleus. Scale bar 10 μm. Insets: 10x
4 magnification.

5

Fig. 6. Forced homo-oligomerization rescues the inhibitory function of the N-terminally truncated ORF6. **a**, FKBP homo-dimerizes in the presence of the B/B homodimerizer. Dose-response curves for the (top left) full-length ORF6^{CoV2}, (top right) ALFA-CT, (bottom left) ALFA-FKBP-CT, and (bottom right) ALFA-(FKBP)₂-CT, where the CT refers to the C-terminal region (residue 38-61) of ORF6^{CoV2}. Green and red colors correspond to the absence and presence of 500 nM B/B homodimerizer, respectively. **b**, The dose-response curve for ALFA-p53TD-CT, where p53TD is the tetramerization domain (residues 326-356) of p53. In **a** and **b**, $n > 1500$ cells for each condition. Error bar shows median and interquartile range in each bin, and the solid line and shaded area represent the best Hill function fit and the corresponding 95% confidence interval, respectively. NUP98 and ALFA immunofluorescence images of cells transfected with **c**, ALFA-CT, **d**, ALFA-(FKBP)₂-CT in the (top) absence and (bottom) presence of 500 nM B/B homodimerizer, and **e**, ALFA-p53TD-CT. Samples were focused on the

- 1 midplane of the nucleus. Scale bar 10 μ m. Insets: 10x magnification. **f**, Proposed model. The N-terminal
- 2 region (NT) of ORF6 drives the oligomerization, leading to cross-linking of the FG domains of NUP98
- 3 at the nuclear pores via multivalent binding of the C-terminal region (CT).